Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant
expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment …

This chapter summarizes the knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and the treatment modalities, including novel breakpoint cluster region‐v …

Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a
biphasic or triphasic clinical course in which a benign chronic phase is followed by …

The role of molecular monitoring for patients with chronic myeloid leukemia (CML) is
multifaceted. Milestone measurements up to 18 months of first-line imatinib therapy are …

The course of chronic myeloid leukemia (CML) and the response to treatment with tyrosine
kinase inhibitors (TKIs) are best monitored and assessed using two molecular tests: the first …

Leukemias have traditionally served as model systems for research on neoplasia because
of the easy availability of cell material from blood and marrow for diagnosis, monitoring and …

Chronic myelogenous leukemia (CML) is a hematological stem cell disorder characterized
by excessive proliferation of the myeloid lineage. It has a progressive course typified by the …

The unique molecular characteristic of chronic myeloid leukemia (CML), the disease-
causing ABL (9q34) to BCR (22q11) translocation, has provided an invaluable tool for …

Chronic myeloid leukemia (CML) is the model cancer, demonstrating the clinical benefits of
targeted therapy and the power of molecular diagnostics and monitoring. In CML, the BCR …

Progress in understanding the molecular basis of signal transmission and transduction has
contributed substantially to clarifying the mechanisms of leukemogenesis and of leukemia …